Introduction
Hypereosinophilic syndrome (HES) is characterized by an increase in circulating eosinophils (greater than 1.5 x 109/1) for which there is no known cause. The central nervous system is affected in 30-50% of patients (Chusid et al., 1975; Spry et al., 1983a) , and this usually consists of focal or diffuse cerebral involvement. There have been few reports of peripheral neuropathy in HES (Chusid et al., 1975; Dorfman et al., 1983) and none in which severe peripheral neuropathy was the presenting feature. We describe a patient with HES who presented with a peripheral neuropathy and review the literature on peripheral neuropathy in HES.
Case report A 21 year old man presented in April 1983 with pain in his calves and forearms, paraesthesiae of the hands and feet and impairment in handgrip of 4 weeks duration. He had general malaise and systematic enquiry revealed an episode of amaurosis fugax 3 weeks before admission. Fifteen months previously asthma had been diagnosed but this was well controlled on salbutamol and beclomethasone inhalers. There was no history of atopy, and skin tests to various allergens including aspergillus were negative apart from a positive reaction to house dust mite. At presentation he was pyrexial and looked unwell. Cardiovascular, respiratory and abdominal examination was normal. He had weakness and wasting of all the intrinsic muscles of the hands which was more marked on the left (Figure 1 ). There was weakness of elbow flexion and extension bilaterally with a severe left foot drop and slight distal weakness in the right leg. Sensation was impaired in a glove and stocking distribution with reduction ofpinprick and light touch sensation to the level of wrists and ankles respectively. Knee 
Discussion
This patient meets the diagnostic criteria for HES with persistent eosinophilia without demonstrable cause. This is a condition more common in males which usually presents between the third and sixth decades. In earlier reports of HES, peripheral neuropathy usually developed after cardiac or respiratory manifestation (Chusid et al., 1975; Dorfman et al., 1983) . Five cases of peripheral neuropathy confirmed by nerve conduction studies have been described, the main features of which are summarized in Table II . Chusid et al. (1975) , in their review of the literature, described four other cases; one ofthese had no neurological signs (Case Records, 1970) , two had hyperreflexia and extensor plantars (Gardener-Thorpe et al., 1971; Yam et al., 1972) and the fourth had severe arterial disease (Novack et al., 1971) . Our case would appear to be the first report of HES presenting with peripheral neuropathy, a feature which is an uncommon complication of the condition. Other features of HES, notably gastrointestinal involvement, subsequently developed in our patient. Of the five previously reported cases, three showed gradual improvement with corticosteroid therapy (Dorfman et al., 1983) , whilst two (Chusid et al., 1975) had no response to corticosteroids or cyclophosphamide. While spontaneous improvement of the peripheral neuropathy may have occurred in our patient it seems more likely that corticosteroid therapy was of benefit in view of his eosinophil response. The sural nerve biopsy showed no evidence of eosinophilic infiltration or arteritis in keeping with recent work which suggests that neural damage may be neurotoxin mediated. Eosinophils have been shown to contain neurotoxic substances responsible for the 'Gordon phenomenon' (Durack et al., 1979) , a syndrome of muscular rigidity, ataxia and progressive paralysis, first described in laboratory animals following intraventricular injection oflymph node homogenates from patients with Hodgkin's disease (Gordon, 1933) . Histologically, loss of Purkinje cells, vacuolation of the myelin sheath and axonal degeneration occurs, with peripheral nerve damage occasionally seen. Several eosinophil granule proteins have been purified and shown to reproduce the Gordon phenomenon. These include eosinophil-derived neurotoxin (Durack et al., 1981) ; eosinophil cationic protein and eosinophil protein X (Fredens et al., 1982) . Eosinophil cationic protein also has specific toxic effects on the myocardial cell membrane (Spry et al., 1983b) and inhibits certain enzymes involved in mitochondrial respiration (Tai et al., 1982) . We could detect no evidence of myocardial involvement in this case but it appears likely that the severe peripheral neuropathy may have been mediated by a circulating eosinophil neurotoxin. 
